anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a Chinese herbal medicine compound preparation. The Chinese herbal medicine compound preparation is characterized by comprising, by weight, 8-30 parts of sedum aizoon, 2-20 parts of conocephalum conicum, 2-20 parts of liverwort, 6-20 parts of radix paeoniae alba and 1-10 parts of sphagnum moss. The Chinese herbal medicine compound preparation further comprises acceptable pharmaceutical adjuvants in pharmacy, and the acceptable pharmaceutical adjuvants include medical carriers, diluents, excipients and the like. The Chinese herbal medicine compound preparation can be prepared into tablets, capsules, linimentum, paste, coating agents, emulsions, nanoparticle emulsions, powder injections, injections and the like. According to another implementing scheme, the invention provides application of the Chinese herbal medicine compound preparation or a pharmaceutical composition to treatment of the bee venom, scorpion venom and snake venom. According to another implementing scheme, the invention provides application of the Chinese herbal medicine compound preparation or the pharmaceutical composition to preparing medicines for treating the bee venom, the scorpion venom and the snake venom. The Chinese herbal medicine compound preparation has the beneficial effects that the effects of treating the bee venom, the scorpion venom and the snake venom are achieved; the evolution speed of the disease course of a patient is decreased; time is won for rescuing; the difficulty that the effective medicines for treating the bee venom are in lack on clinic at present is overcome; and the application prospect is wide.
All enrolled participants will complete the remotely delivered 8 week MSC intervention (described in interventions). Participants are encouraged to practice the formal meditations and/or informal skills taught each week between sessions. Participants will give feedback on self-compassion activities and the overall intervention. They will also complete several measures before, during, and after the intervention and at 3-month follow-up.
Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
PROBLEM TO BE SOLVED: To obtain a composition for an oral cavity capable of preventing dental caries by neutralizing an acid produced in a dental plaque. SOLUTION: This composition for an oral cavity comprises fine calcium carbonate containing >=50wt.% particles having a size of primary particles as a particle diameter within the range of 0.04-3μm. Since the calcium carbonate having the specific particle diameter is capable of reaching even a narrow site readily causing dental caries and is hardly soluble in water, the calcium carbonate easily stays in a dental plaque. Thereby, the neutralizing reaction is initiated only when an acid is produced in the dental plaque to prevent teeth from being decalcified. Calcium ions are released therefrom to promote the recalcification. The calcium carbonate is blended in an amount of especially preferably 1-30% based on the whole product due to the manifestation of high viscosity characteristics when the blended amount is too large.
Methods and apparatus are provided for the noninvasive detection and measurement of macular pigments such as carotenoids in macular tissue. In one technique, lipoftiscin autofluorescence spectroscopy is utilized for macular pigment measurements. In autofluorescence spectroscopy, the emission of lipoftiscin is excited at two wavelengths: one wavelength that overlaps both the macular pigment and lipofuscin absorption and another wavelength that lies outside the macular pigment absorption range but that still excites the lipofuscin emission. The macular pigment absorption is then derived from the different lipoftiscin emission intensities in the macula and peripheral retina. In another technique, both autofluorescence spectroscopy, as described above, and resonance Raman spectroscopy are used to identify and quantify the presence of carotenoids in macular tissue. In using resonance Raman spectroscopy, laser light is directed onto the eye tissue and the scattered light is then spectrally filtered and detected. The frequency difference between the laser light and the Raman scattered light is known as the Raman shift. The magnitude of the Raman shift is an indication of the type of chemical present, and the intensities of the Raman signal peaks correspond directly to the chemical concentration.
ENGERIX-B is generally well tolerated. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between ENGERIX-B and plasma-derived vaccines. In 36 clinical studies, a total of 13,495 doses of ENGERIX-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of ENGERIX-B. Using a symptom checklist,† the most frequently reported adverse reactions were injection site soreness (22%) and fatigue† (14%). Other reactions are listed below.
Background. Subcutaneous immunotherapy (SCIT) is a potential disease-modifying therapy effective for treatment of various allergic disorders. Pain and fear are common concerns of children, which can pose stress and result in negative experiences. The purpose of this study was to evaluate and compare the effectiveness of three marketed distraction devices and ethyl chloride spray (a routinely used topical anesthetic agent for painful procedures), the current clinical standard of care in reducing the perception of needle pain during SCIT administration in children. Methods. 40 children, aged 4-17 years, receiving SCIT with use of one of three alternative pain therapies or with standard practice were enrolled. Participants were randomly assigned to one of the pain-modifying interventions. The three interventional groups were ShotBlocker® (Bionix, Toledo, OH, USA), Buzzy® I (Pain Care Labs, Atlanta, GA, USA) (vibration only), and Buzzy® II (vibration with ice). Control group was ethyl chloride spray. The study consisted of two visits during SCIT administration process. Results. Of these 40 children, 12 received the ShotBlocker, 8 received the Buzzy I, 11 received the Buzzy II, and 9 received ethyl chloride spray (control group). Conclusions. There were no significant differences found between each of the distraction devices and between the control group. Type II error/false negative finding cannot be ruled out because of a small sample. Therefore, we cannot conclude that no true difference exists between each distraction device and the control group simply because of occurrence of a non-significant P-value in our study.
Psychiatric adverse experiences have been reported in patients treated with modafinil. Modafinil and armodafinil (NUVIGIL) are very closely related. Therefore, the incidence and type of psychiatric symptoms associated with armodafinil are expected to be similar to the incidence and type of these events with modafinil.

Postmarketing adverse events associated with the use of modafinil have included mania, delusions, hallucinations, suicidal ideation and aggression, some resulting in hospitalization. Many, but not all, patients had a prior psychiatric history. One healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of modafinil and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation.

In the controlled trial NUVIGIL database, anxiety, agitation, nervousness, and irritability were reasons for treatment discontinuation more often in patients on NUVIGIL compared to placebo (NUVIGIL 1.2% and placebo 0.3%). In the NUVIGIL controlled studies, depression was also a reason for treatment discontinuation more often in patients on NUVIGIL compared to placebo (NUVIGIL 0.6% and placebo 0.2%). Two cases of suicide ideation were observed in clinical trials. Caution should be exercised when NUVIGIL is given to patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with NUVIGIL administration, consider discontinuing NUVIGIL.
The advent of modular porous metal augments has ushered in a new form of treatment for acetabular bone loss. The function of an augment can be seen as reducing the size of a defect or reconstituting the anterosuperior/posteroinferior columns and/or allowing supplementary fixation. Depending on the function of the augment, the surgeon can decide on the sequence of introduction of the hemispherical shell, before or after the augment. Augments should always, however, be used with cement to form a unit with the acetabular component. Given their versatility, augments also allow the use of a hemispherical shell in a position that restores the centre of rotation and biomechanics of the hip. Progressive shedding or the appearance of metal debris is a particular finding with augments and, with other radiological signs of failure, should be recognized on serial radiographs. Mid- to long-term outcomes in studies reporting the use of augments with hemispherical shells in revision total hip arthroplasty have shown rates of survival of > 90%. However, a higher risk of failure has been reported when augments have been used for patients with chronic pelvic discontinuity.
<P>PROBLEM TO BE SOLVED: To manage the act of nursing in order to properly execute the act of nursing.  <P>SOLUTION: A problem preparation support part 30 supports the preparation of the items of nursing problems cooperatively with a first database 32 for a patient. A plan preparation support part 34 retrieves a second database 36 based on the prepared items of the nursing problem in order to support the preparation of the nursing plan. An instruction part 38 instructs the execution of the nursing items included in the prepared nursing plan cooperatively with a third database 40. A communication part 52 accepts the execution results of the nursing items, and outputs them to a recording part 60. A nurse inputs evaluations to the execution results of the nursing items to an operation device 62. The input evaluations are recorded in the recording part 60. A management part 56 associates the mutually corresponding items among the items of the nursing problem, the nursing items included in the nursing plan, the execution results and evaluations stored in the recording part 60.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
Teratogenic effects 

Pregnancy Category C: Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON should be given to a pregnant woman only if clearly needed. The risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a pregnant woman with exocrine pancreatic insufficiency. Adequate caloric intake during pregnancy is important for normal maternal weight gain and fetal growth. Reduced maternal weight gain and malnutrition can be associated with adverse pregnancy outcomes.
Cancer patients commonly use morphine to alleviate advanced pain. Studies have shown that morphine may influence and intervene in the malignancy of various cancers, but its role and effects on pancreatic cancer are less studied. This study aims to examine how morphine affects pancreatic cancer and its possible mechanisms. In vitro experiments were conducted using the CCK-8 experiment, colony formation experiment, EdU test, wound healing experiment, and transwell migration and invasion experiment. Tumor xenograft tests were employed to investigate the in vivo impact of morphine on pancreatic cancer. The Western blot (WB) assay was used to detect possible changes in key proteins of the related signaling pathway. Our experimental results showed that low concentrations of morphine (25 µM) promoted the progression of pancreatic cancer, while high concentrations of morphine (100 µM) inhibited its progression. Further, we demonstrated that morphine may interfere with the progression of pancreatic cancer by acting on the p38/JNK signaling pathway. Morphine may affect pancreatic cancer progression through the p38/JNK pathway in a bidirectional manner at different concentrations.
A particular  Bifidobacterium  spp. strain or particular  Lactobacillus  spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular  Bifidobacterium  spp. strain or particular  Lactobacillus  spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases.
A method and system for diagnosing a subject with respect to a pancreatic cancer disease state. Peptide structure data corresponding to a biological sample obtained from the subject is received. The peptide structure data is analyzed using a supervised machine learning model to generate a disease indicator that indicates whether biological sample evidences the PC disease state based on at least 3 peptide structures selected from a group of peptide structures of Group I identified in Table 1 or of Group II of Table 8. The group of peptide structures in Table 1 or Table 8 comprises a group of peptide structures associated with the PC disease state. The group of peptide structures is listed in Table 1 with respect to relative significance to the disease indicator. A diagnosis output is generated based on the disease indicator
OBJECTIVES: Optimal management of obese patients with early-stage cervical cancer is debated despite evidence of non-inferior survival in obese patients undergoing radical hysterectomy with pelvic lymphadenectomy (RH) compared to primary radiation with or without radiosensitizing chemotherapy (RT). Objectives included describing patient factors affecting disposition to RH versus RT; comparing RH outcomes for obese (BMI >30 mg/m2) and non-obese patients; and comparing differences in recurrence free survival (RFS) and overall survival (OS).
METHODS: This was a single institution cohort study of all cervical cancer patients who underwent RH or were candidates for RH based on clinical stage. Demographic, clinicopathologic and treatment outcomes were collected and analyzed.
RESULTS: RT patients (n = 39, 15%) had a higher BMI (p = 0.004), older age (p < 0.001), more life-limiting comorbidities (LLC) (p < 0.001), larger tumor size (p = 0.001), and higher clinical stage (p = 0.013) compared to RH patients (n = 221, 85%). On multivariable survival analysis there was no difference in OS based on treatment modality; significant predictors of worse OS were larger tumor size, higher number of LLC and recurrence. Among the RH group, obese patients had a longer operative time (p = 0.01) and more LLC (p = 0.02); there were no differences in demographic or clinicopathologic characteristics, operative outcomes, RFS or OS compared to non-obese patients.
CONCLUSION: In this cohort of RH-eligible cervical cancer patients, BMI was independently associated with disposition to RT. Studies demonstrate that RH is feasible and safe in obese patients with no difference in RFS or OS when compared to non-obese patients. Thus, the decision for disposition to RT should not be based on obesity alone.
Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
###  Teratogenic Effects: Pregnancy Category B.

There are no adequate and well-controlled studies of ATROVENT HFA (ipratropium bromide) Inhalation Aerosol in pregnant women. ATROVENT HFA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral reproduction studies were performed in mice, rats and rabbits at doses approximately 200, 40,000, and 10,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults (on a mg/m2 basis at maternal doses in each species of 10, 1,000, and 125 mg/kg/day, respectively). Inhalation reproduction studies were conducted in rats and rabbits at doses approximately 60 and 140 times, respectively, the MRHDID in adults (on a mg/m2 basis at maternal doses of 1.5 and 1.8 mg/kg/day, respectively). These studies demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. Embryotoxicity was observed as increased resorption in rats at oral doses approximately 3,600 times the MRHDID in adults (on a mg/m2 basis at maternal doses of 90 mg/kg/day and above). This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration.
The invention relates to a treatment method of pre-auricular fistula inflammation. According to the method, treatment is carried out through disinfection and external application of a plaster. The treatment method comprises the following specific steps: (a) mixing gentamicin, hydrogen peroxide and hexadecadrol, wherein the weight part ratio of gentamicin to hydrogen peroxide to hexadecadrol is 1 to 2 to 0.5; (b) dipping a cotton swab into the mixed disinfectant composed of gentamicin, hydrogen peroxide and hexadecadrol, and applying the mixed disinfectant to the position with the pre-auricular fistula; and (c) applying the plaster, wherein the raw materials of the applied plaster comprise folium nerviliae fordii, dandelion, wild chrysanthemum flowers, honeysuckle flowers, radix bupleuri, radix angelicae, cortex moutan, plantain herb, sichuan coptis root and spina gleditsiae. The method of dipping the cotton swab into the mixed disinfectant can be replaced by the method of sucking the disinfectant by adopting a needle tube and washing the pre-auricular fistula by adopting the disinfectant. The method is suitable for patients with pre-auricular fistula fester, and in the step of applying the plaster, squama manitis, radix platycodi, radix angelica sinensis and coix seeds are added. The method has the advantages that the surgery is not needed, no scars are left, the operation is easy, the pre-auricular fistula inflammation can be eliminated, and the peculiar smell can be removed.
BACKGROUND: Enfortumab vedotin (EV), an antibody-drug conjugate that targets Nectin-4, is used for patients with metastatic urothelial carcinoma who have experienced progression on platinum-based chemotherapy and checkpoint inhibitors. Despite the widespread use of the drug, evidence remains scarce regarding clinical indicators that can predict the response to EV treatment.
OBJECTIVE: We aimed to explore the predictive value of clinical indicators derived from peripheral blood tests for treatment responses to EV.
METHODS: We utilized records of 109 patients with metastatic urothelial carcinoma treated by EV from our multi-institutional dataset. Receiver operating characteristic curve analyses for predicting objective responses including several indicators from blood examinations, such as C-reactive protein-albumin ratio (CAR), hemoglobin, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and lactate dehydrogenase, were performed. The optimal cutoff points were determined by the Youden index. Logistic regression analyses for achieving objective responses to EV treatment were performed among these indicators.
RESULTS: The median age of the cohort was 74 years, and the median follow-up duration was 10 months for the entire group. Median overall survival and progression-free survival from the initiation of EV were 12 and 6 months, respectively. The objective response rate and disease control rate were 48% and 70%, respectively. The receiver operating characteristic curve analysis aimed at predicting the achievement of an objective response to EV showed that the concordant index for the CAR was 0.774, significantly surpassing other indicators such as hemoglobin level, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and serum lactate dehydrogenase. The Youden index identified an optimal cutoff value of 1 for CAR (mg/L for C-reactive protein and g/dL for serum albumin level) in predicting the objective response to EV treatment. Using the cutoff value for the CAR, the cohort was divided into 32 patients (29%) with lower CAR and 77 patients (71%) with higher CAR. The objective response rate was observed to be 84% in the lower CAR group and 32% in the higher CAR group (p < 0.0001). A logistic regression analysis revealed that an Eastern Cooperative Oncology Group Performance Status ≥1 (p = 0.04) and a CAR ≥1 (p < 0.001) were identified as independent predictors for the objective response to EV.
CONCLUSIONS: The evaluation of the CAR from a concise blood examination at the initiation of EV could effectively predict the treatment response to EV in patients with metastatic urothelial carcinoma after the progression of platinum-based chemotherapy and checkpoint inhibitors.
Reports of necrotizing fasciitis of the perineum (Fournier's Gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors. Cases have been reported in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death. 

Patients treated with INPEFA presenting with pain, tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue INPEFA, closely monitor blood glucose levels, and provide appropriate alternative therapy for heart failure.